Intelligence Feed event · Equity · 2026-08-03

    Curium to Acquire Lantheus in $8 Billion Radiopharma Deal

    Question

    Curium to Acquire Lantheus in $8 Billion Radiopharma Deal

    Direct answer

    The acquisition of Lantheus by Curium is a major consolidation move in the radiopharmaceutical space. The $102.50 cash price provides immediate liquidity, while the $12 CVR suggests confidence in the pipeline's future diagnostic and therapeutic potential. This follows a trend of large-scale acquisitions in the biotech and pharma sectors as companies seek to dominate specialized niches like radiopharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Curium to Acquire Lantheus in $8 Billion Radiopharma Deal”, revision 1, evidence through 2026-08-03. https://marketontology.com/market-events/2026-08-03/curium-to-acquire-lantheus-in-8-billion-radiopharma-deal-fc9087

    EQUITY
    Curium to Acquire Lantheus in $8 Billion Radiopharma Deal
    The acquisition of Lantheus by Curium is a major consolidation move in the radiopharmaceutical space. The $102.50 cash price provides immediate liquidity, while the $12 CVR suggests confidence in the pipeline's future diagnostic and therapeutic potential. This follows a trend of large-scale acquisitions in the biotech and pharma sectors as companies seek to dominate specialized niches like radiopharmaceuticals.
    LNTH
    Impact
    81
    AUG 3
    SIG
    100%
    LNTH
    Curium to Acquire Lantheus in $8 Billion Radiopharma Deal
    The acquisition of Lantheus by Curium is a major consolidation move in the radiopharmaceutical space. The $102.50 cash price provides immediate liquidity, while the $12 CVR suggests confidence in the pipeline's future diagnostic and therapeutic potential. This follows a trend of large-scale acquisitions in the biotech and pharma sectors as companies seek to dominate specialized niches like radiopharmaceuticals.
    → Sector consolidation via cash acquisition and CVR structure.
    Impact
    The acquisition of Lantheus by Curium is a major consolidation move in the radiopharmaceutical space. The $102.50 cash price provides immediate liquidity, while the $12 CVR suggests confidence in the pipeline's future diagnostic and therapeutic potential. This follows a trend of large-scale acquisitions in the biotech and pharma sectors as companies seek to dominate specialized niches like radiopharmaceuticals.
    Affected
    LNTH
    Transmission
    Sector consolidation via cash acquisition and CVR structure.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month